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Abstract: There are scarce data available regarding the impact of hidradenitis suppurativa (HS) on
fertility, course and outcome of pregnancy and risk associated with treatments. The aims of this study
are (1) to describe the clinical profile of HS women of childbearing age with and without accom-
plished reproductive desires and (2) to describe the prescribed treatments based on the fulfillment
of reproductive intentions. We conducted a prospective observational study that included 104 HS
women of childbearing age, 50.96% (53/104) with unfulfilled reproductive desires. These women
were younger (29.08 vs. 42.06 years, p < 0.001), less frequently married and higher educated than
women with fulfilled reproductive desires. Their age of disease onset was lower, but disease duration
was shorter, in concordance with a lower International Hidradenitis Suppurativa Severity Score
System (IHS4) and lower number of draining tunnels. Combined oral contraceptives were more
frequently prescribed in women with unfulfilled reproductive desires (30.19% vs. 9.80%, p = 0.013)
while biologics were less used in this group (3.77% vs. 13.73%, p = 0.08). In conclusion, a higher
educational level and an earlier disease onset, with potential implications in finding a partner, may
make the fulfillment of reproductive desires difficult for patients with HS. This study could help
clinicians to achieve a better understanding of the specific characteristics of HS during childbearing
age and consider reproductive desires when making treatment decisions.
Keywords: hidradenitis suppurativa; acne inversa; pregnancy; reproductive behavior
1. Introduction
Reproductive health and the fulfillment of genetic desires are an important part of
patients’ quality of life that may be affected by hidradenitis suppurativa (HS) [1]. HS is a
chronic, recurrent, debilitating inflammatory skin disease of the hair follicle which usually
presents after puberty with painful, deep-seated inflamed lesions in the apocrine gland-
bearing areas of the body, most commonly the axillae and the inguinal and anogenital
regions [2]. It has an estimated prevalence rate of around 1% [3], and it disproportion-
ally affects women of childbearing age [4]. Nevertheless, there are little data available
regarding the impact of HS on reproductive desire, pregnancy and the risk associated with
treatments [5].
The fertility rate is lower in patients with other inflammatory diseases such as psoria-
sis [6], rheumatoid arthritis and inflammatory bowel disease [7]. HS is the dermatological
disease with the greatest impact on patients’ quality of life [8] and has a similar impact
to other non-dermatological conditions such as cardiovascular disease, cancer, diabetes
Life 2021, 11, 277. https://doi.org/10.3390/life11040277 https://www.mdpi.com/journal/life
Life 2021, 11, 277 2 of 13
mellitus and chronic obstructive pulmonary disease [9]. HS clinical manifestations cause
pain, itching, unpleasant odor and suppuration, among other symptoms, which make life
difficult for patients [10] and may have an impact on pregnancy desire. Moreover, HS has
a negative effect on sexual function, which is worse in women with active lesions in the
groin and genital areas [11]. Poor self-esteem and body image [12,13] and increased risk of
anxiety and depression [14,15] may also decrease reproductive desire. Furthermore, HS is
associated with comorbidities such as obesity, Crohn’s disease, diabetes type 2 and cardio-
vascular disease [16], which contribute to a lower fertility rate. The role of the diet is also
crucial in fertility rates, as it has been proved that a healthy diet and doing exercise increase
the number of natural conceptions [17]. Moreover, the lack of adherence to a Mediterranean
diet is associated with more severe HS [18] and polycystic ovary syndrome [19]. High
levels of tumor necrosis factor (TNF)-alpha have been associated with both a pathophysio-
logical role in HS [20] and obstetric complications [21], which may explain a decrease in
the fertility rate in HS women. In fact, it has been observed that treatment with blockage
TNF might be a useful treatment for infertility [21].
It also should be considered that some medications commonly prescribed for HS might
affect the reproductive function. There are some teratogenic treatments forbidden before
and during pregnancy, but there is scarce information on most of them [22]. Clinicians
prescribing a drug for women of childbearing age have to consider possible interference
with conception, the contraceptive failure caused by medication interactions and the
potential risk to mother and fetus caused by the drug if pregnancy occurs [23]. The
implications of treatment should be considered in all women with HS who are sexually
active, even if they are not actively planning to become pregnant, as approximately half of
all pregnancies are unplanned [24] and women usually discover they are pregnant between
weeks 4 and 7, a critical window for early fetal development [25].
Thus, the objectives of our study were: (1) to describe the clinical profile of HS women
of childbearing age with and without accomplished reproductive desires, (2) to describe
the prescribed treatments based on the fulfillment of reproductive desire and the possible
implication of treatments on pregnancy and fertility and (3) to describe the clinical profile
of HS women receiving first-line biologics based on the fulfillment of reproductive desire.
2. Materials and Methods
2.1. Design: Prospective Observational Study
Patient selection. This study included all women of childbearing age with a clinical
diagnosis of HS who attended the HS Clinic of Hospital Universitario Virgen de las
Nieves, Granada, Spain. The diagnosis of HS was performed by a dermatologist relying
on clinical findings of (1) typical HS lesions, (2) predilection for intertriginous sites and (3)
recurrence [26]. Clinical information was gathered if inclusion and exclusion criteria were
met at two different time points: (1) at the first visit to the HS clinic or (2) at the visit where
biologic treatment was initiated. A patient’s clinical information could be included in both
analyses if biologic treatment was prescribed at the first visit to the HS clinic. The clinical
information of a single patient at each time point could also be included in both analyses if
the patient was prescribed classic systemic therapy (for example, oral antibiotics) at the
first visit to the HS clinic, and afterwards, the patient was prescribed biologic treatment
following the recommendations of current treatment guidelines [10]. The flowchart of the
participants is shown in Figure 1.
Inclusion criteria:
- HS women of childbearing age (15–49 years-old);
- Women who were prescribed systemic therapy for the treatment of HS.
Exclusion criteria:
- HS women who did not sign the written consent form or young women under 18
whose legal representative did not sign the informed consent;
- Climacteric women.
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Figure 1. Flowchart of the participants. 
Inclusion criteria:  
- HS women of childbearing age (15–49 years-old); 
- Women who were prescribed systemic therapy for the treatment of HS. 
Exclusion criteria:  
- HS women who did not sign the written consent form or young women under 
18 whose legal representative did not sign the informed consent; 
- Climacteric women.  
2.2. Variables of Interest  
2.2.1. Main Variables of Interest 
Accomplishment of reproductive desires. Women were asked if they wanted to have 
a baby now or in the future during the visit, and they were gathered into two groups. If 
the answer was not, women were classified in the group of women with fulfilled repro-
ductive desires, while if they answered yes, they were included in the group of women 
with unfulfilled reproductive desires.  
This information was gathered at the first visit to the HS clinic and reassessed by 
protocol in all women of childbearing age every time a patient was prescribed a systemic 
treatment. The compatibility of a treatment with pregnancy, fertility and drug washout 
times was explained to the patient before a drug was prescribed. The patient had to un-
derstand and give consent (oral or written as per legal requirements) to the treatment. 
2.2.2. Other Variables of Interest 
Clinical, sociodemographic and biometric variables were recorded by means of clin-
ical interview and physical examination. Sociodemographic characteristics included sex, 
age, civil status, level of education, body mass index (BMI), smoking habit, alcohol con-
sumption and family history of HS. Clinical features included age at HS onset, disease 
duration, Hurley stage, number of affected areas, previous medical and surgical treat-
ments, nodules and abscess and draining tunnel count.  
  
Figure 1. Flowchart of the participants.
2.2. Variables of Interest
2.2.1. Main Variables of Interest
A complishment of reproductive desires. Women were asked if they wanted to have a
baby n w or in t e future during the visit, and they were gathered into two groups. If the
answer was not, women wer clas ified in the group of women wi h ulfilled reproductive
de res, wh le if they answered yes, they were included in the group of women with
unfulfilled reproductive desires.
T i information was gathered at the first visit to the HS clinic and reassessed by
protocol in all women of childbearing age every time a patient was prescribed a systemic
treatment. The compatibility of a treatment with pregnancy, fertility and drug washout
times was explained to the patient before a drug was prescribed. The patient had to
understand and give consent (oral or written as per legal requirements) to the treatment.
2.2.2. Other Variables of Interest
Clinical, sociodemographic and biometric variables were recorded by means of clinical
interview and physical examination. Sociodemographic characteristics included sex, age,
civil status, level of education, body mass index (BMI), smoking habit, alcohol consumption
and family history of HS. Clinical features included age at HS onset, disease duration,
Hurley stage, number of affected areas, previous medical and surgical treatments, nodules
and abscess and draining tunnel count.
2.3. Ethics
All patients agreed with the treatment regimen and signed a written consent form
to use their personal data for the present study. This study was approved by the Ethics
Committee of the Hospital Universitario Virgen de las Nieves the 22nd of December 2019,
reference number 2390-N-19, and is in accordance with the H lsinki Declaration.
2.4. Statistical Analysis
Descriptive statistics were used to evaluate the ch racteristics of he ample. The
Kolmogorov–Smirnov test was us to check the nor ality of the variables. Continuous
data were expres ed as mea ± standard deviation (SD) or as the median (25th–75th
percentile). The absolute and relative frequency distributions were estimated for qualitative
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variables. The student’s t-test or the Wilcoxon–Mann–Whitney test were used to compare
continuous data (such as age or total abscess and inflammatory nodule (AN) count), and
the χ2 test or Fisher’s exact test were applied to nominal data where necessary (such as
civil status or Hurley stage). The study size was calculated to determine the proportion
of patients with HS and unfulfilled reproductive desires with an alpha error of 5% and a
power of 20%; considering a reference population of 450,000 inhabitants, and an estimated
prevalence of HS in the general population of 1% [3], the estimated sample size was
49 patients. Significance was set for all tests at two tails, p < 0.05. Statistical analyses were
performed using JMP version 14.1.0 (SAS institute, Cary, NC, USA).
3. Results
3.1. Demographic and Clinical Features of Women Based on the Fulfillment of Reproductive Desire
One hundred twenty-two women with HS were seen at our HS clinic between Febru-
ary 2017 and April 2020, with 85.2% of them (104/122) being of childbearing age: 49.04%
(51/104) had fulfilled reproductive desires and 50.96% (53/104) had unfulfilled reproduc-
tive desires. Demographic and clinical features are shown in Table 1.
Table 1. Demographic and clinical features of patients based on fulfillment of reproductive desires.
Variables Women with FulfilledReproductive Desires (N = 51)
Women with Unfulfilled
Reproductive Desires (N = 53) p
Age (years) 42.06 (SD 6.46) 29.08 (SD 8.90) <0.001 *
Civil status










Mandatory education level (yes) 30 (58.82%) 44 (83.02%) 0.007 *
Unemployed (yes) 26 (50.98%) 19 (35.85%) 0.120
BMI kg/cm2 32.64 (SD 7.61) 28.56 (SD 5.29) 0.002 *
Smoking habit (yes) 31 (60.78%) 23 (43.40%) 0.076
Alcohol consumption (yes) 9 (17.65%) 12 (22.64%) 0.526
Age of onset (years) 24.63 (SD 10.96) 18.23 (SD 7.16) 0.006 *
Disease duration (years) 17.43 (SD 9.29) 10.85 (SD 6.36) <0.001 *












AN count 1.86 (SD 2.07) 2.68 (SD 3.24) 0.130
Draining tunnels count 1.14 (SD 1.58) 0.49 (SD 0.80) 0.009 *
IHS4 7.33 (SD 6.75) 5.51 (SD 5.19) 0.124
Number of affected areas 1.90 (SD 1.06) 1.60 (SD 1.00) 0.145
Number of previous medical
treatments 1.96 (SD 1.57) 1.68 (SD 1.36) 0.330
Number of previous surgeries 0.98 (SD 1.21) 1.04 (SD 1.81) 0.850
AN: total abscess and inflammatory nodule count; BMI: body mass index; IHS4: International Hidradenitis Suppurativa Severity Score
System. Data are expressed as relative (absolute) frequencies and means (standard deviation (SD). The Student’s t test for independent
samples was used to compare continuous variables and the chi-square test or Fisher’s exact test, as appropriate, were applied to compare
categoric data. Two-tailed * p < 0.05 was considered statistically significant in all tests.
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Regarding sociodemographic features, the women with fulfilled reproductive desires
were older, and more frequently married or living with a partner. The proportion of patients
with compulsory education was higher among women with unfulfilled reproductive desires
and also in the proportion of employed women. BMI was higher among patients with
fulfilled reproductive desires, as was the number of active smokers.
With respect to HS clinical features, the age of disease onset was lower in women with
unfulfilled reproductive desires, but disease duration was longer in women with fulfilled
reproductive desires. In concordance with longer disease duration, the Hurley stage, IHS4
and number of draining tunnels was higher in women with fulfilled reproductive desires.
3.2. Treatment Patterns in HS Women of Childbearing Age
Global treatment patterns and their classification based on the fulfillment of reproduc-
tive desires are shown in Table 2. Pregnancy category (A B C D X), pregnancy impairments,
recommended washout period before becoming pregnant and implications on pregnancy
and fertility issues are also shown.
Intralesional corticosteroids were the most used treatment in both groups, followed
by oral doxycycline, oral contraceptives and oral clindamycin. The prescription frequency
was similar between groups except for combined oral contraceptives. They were more
frequently prescribed in women with unfulfilled reproductive desires.
Although non-statistically significant differences were found, the only treatment in
the X category, acitretin, was prescribed less in woman with unfulfilled reproductive de-
sires. Regarding category D treatments (doxycycline, levonorgestrel-releasing intrauterine
system, spironolactone and systemic corticosteroids), the prescription rate was similar
between groups. Biologics were used more in women with fulfilled reproductive desire
13.73% (7/51) vs. 3.77% (2/53), p = 0.08, both adalimumab and infliximab.
3.3. Demographic and Clinical Features of Women of Childbearing Age Receiving First-Line
Biologic Treatment
Fourteen women started their first-line biologic treatment during follow-up at our HS
clinic, Table 3. In total, 42.85% (6/14) of women had fulfilled reproductive desires, while
57.14% (8/14) had unfulfilled reproductive desires. Women with unfulfilled reproductive
desires were younger than women with fulfilled reproductive desires, presenting an earlier
disease onset.
All women with fulfilled reproductive desires were married or living with a partner,
while in the group with unfulfilled reproductive desires, half were married, and half were
separated. BMI, smoking habit, alcohol consumption and family history of HS were similar
in both groups.
In concordance with a higher disease duration severity evaluated by Hurley stage, the
draining tunnel count was higher in women with fulfilled reproductive desires, while the
abscess–nodule count was higher in women with unfulfilled reproductive desires. The
mean IHS4 was similar in both groups. The number of affected areas and number of
previous medical treatments was similar between groups. The number of previous surgical
treatments was higher in woman with unfulfilled reproductive desires.
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Table 2. Treatments of the sample based on fulfillment of reproductive desires, pregnancy category, washing time recommendation to get pregnant, possible impact on pregnancy
and fertility.








Desires (N = 53)
p Pregnancy CategoryABCDX








Corticosteroids [22,27] 59 (56.73%) 28 (54.90%) 31 (58.49%) 0.136 C No. Safe in pregnancy Safe in pregnancy
Not reported in
women









33 (31.73%) 13 (25.49) 20 (37.74%) 0.10
B
No. Little or no increased risk
of birth defects in women who




fertility21 (20.19%) 5 (9.80%) 16 (30.19%) 0.013 *
12 (11.54%) 8 (15.69%) 4 (7.55%) 0.231
Oral clindamycin [30] 15 (14.42%) 10 (19.61%) 5 (9.43%) 0.140 B
No. Not contraindicated
during pregnancy, no evidence
of teratogenicity
Safe in pregnancy
No effects on fertility
or mating ability
reported.
Resorcinol [22,31] 8 (7.69%) 4 (7.84%) 4 (7.55%) 1.00 D No. Insufficient safety data One day #




Adalimumab [32] 8 (7.69%) 6 (11.76%) 2 (3.77%) 0.156 B
No. Safety unclear
no increased
risk of adverse birth outcomes
to date
24 No fertility ratereported to date
Levonorgestrel-releasing
intrauterine system [33] 6 (5.77%) 4 (7.84%) 2 (3.77%) 0.432 D
Yes. Ectopic pregnancy,
pregnancy loss, septic abortion 1
# Reversible loss of
fertility
Surgery [22,34] 5 (4.81%) 2 (3.92%) 3 (5.66%) 0.679 B
No.
Lidocaine epinephrine




One day No effect
Spironolactone [35] 4 (3.85%) 3 (5.88%) 1 (1.89%) 0.358 D
No. May affect sex
differentiation for the male
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Table 2. Cont.








Desires (N = 53)
p Pregnancy CategoryABCDX













Colchicine [37] 4 (3.85%) 3 (5.88%) 1 (1.89%) 0.358 C No. Risk of teratogenicity isdiscussed. One day
# Not established
Rifampin [38] 3 (2.88%) 2 (3.92%) 1 (1.89%) 0.614 C
No. Insufficient data. May
increase the risk for maternal
postpartum hemorrhage and
bleeding in the exposed infant
when administered during the








Metformin [39] 2 (1.92%) 0 (0.00%) 2 (3.77%) 0.495 B No Safe in pregnancy No effect
Systemic Corticosteroids
[22,40] 2 (1.92%) 1 (1.96%) 1 (1.89%) 1.00 D
No. Fetal harm can occur with
first trimester use. Small risk of
oral cleft






Infliximab [41] 1 (0.96%) 1 (1.96%) 0 (0.00%) 0.49 B
No. Safety unclear
no increased
risk of adverse birth outcomes
to date
24 Unknown
# If no specified information was found, safety was considered after six half-lives, when 98% of a drug is eliminated from the body. Data are expressed as relative (absolute) frequencies. The chi-square test or
Fisher’s exact test, as appropriate, were applied to compare categoric data. Two-tailed * p < 0.05 was considered statistically significant in all tests.
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Age (years) 46.50 (SD 4.28) 30.13 (SD 11.06) 0.005 *
Civil status











- Mandatory 6 (100.00%) 8 (100.00%) 1
BMI (kg/cm2) 34.39 (SD 5.72) 33.11 (SD 6.68) 0.71
Smoking habit (yes) 3 (50.0%) 3 (37.50%) 0.64
Alcohol consumption (yes) 1 (16.7%) 3 (37.50%) 0.804
Family history (yes) 4 (66.67%) 4 (50.00%) 0.627
Age of onset (years) 26.83 (SD 9.41) 15.50 (SD 5.73) 0.016 *












AN count 1.83 (SD 1.72) 4.13 (SD 5.49) 0.347
Draining tunnels count 2.60 (1.75) 2.00 (SD 1.77) 0.497
IHS4 13.83 (SD 6.88) 14.38 (SD 11.51) 0.921
Number of affected areas 3.33 (SD 1.86) 3.13 (SD 1.13) 0.799
Number of previous medical treatments 4.50 (SD 2.74) 4.25 (SD 1.28) 0.822
Number of previous surgeries 1.00 (SD 0.89) 2.75 (SD 2.25) 0.099
AN: total abscess and inflammatory nodule count; BMI: body mass index; IHS4: International Hidradenitis Suppurativa Severity Score
System. Data are expressed as relative (absolute) frequencies and means (standard deviation (SD). The Student’s t test for independent
samples was used to compare continuous variables, and the chi-square test or Fisher’s exact test, as appropriate, were applied to compare
categoric data. Two-tailed * p < 0.05 was considered statistically significant in all tests.
4. Discussion
In this study, we present the first clinical data describing the characteristics of HS
women based on the accomplishment of their reproductive desires and the potential
treatment impact on fertility, course and outcome of pregnancy.
Regarding sociodemographic features, women with unfulfilled reproductive desires
were younger than women with fulfilled reproductive desires. The possibility of completing
reproductive desires increases over the years [42], so an age difference between the two
groups had been expected. The proportion of women with completed mandatory education
level was higher in women with unfulfilled reproductive desires. This is explained by
low educational level being associated with early maternal age [43], as a delay in the first
childbirth may improve women’s educational and economic opportunities [44,45]. Higher
BMI in women with fulfilled reproductive desires may be explained by their older age,
as BMI is positively correlated with age [46], and the increasing weight gain between
consecutive pregnancies, even in women without pre-existing obesity [47]. Weight gain
is known to contribute to HS pathogenesis [48], while the effect of pregnancy on HS [49]
as well as the effect of HS on pregnancy are unknown [50,51]. Although a high rate of
HS exacerbation during pregnancy and postpartum has been reported, most patients
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did not receive HS-directed medical treatment or care from a dermatologist during their
pregnancy [51]. Having a healthy life could also influence the rate of pregnancies. Having
an unhealthy diet has been related to HS severity [18] and HS severity and polycystic ovary
syndrome [19], factors that could decrease the possibility of being pregnant.
With respect to civil status, the lower proportion of patients married/living with
partner in women with unfulfilled reproductive desire could not only be explained by
age differences. When comparing these data to the civil status standardized by age in
the Spanish population, greater differences were also found in the group with unfulfilled
reproductive desires. The proportion of Spanish women who are married/living with
partner in their 40s is nearly 65%, while in women in their 30s, this rate is around 40% [52].
Our results are in agreement with the Swedish HS Registry, which showed that HS patients
are more frequently unmarried than the general population [53]. This may be explained by
the fact that disease severity may make it difficult to find a partner [54] and have a negative
impact on sex life [1,11]. Early disease onset may also have an influence on the difficulty of
finding a partner as our results observed a higher frequency of single HS women in the
early-onset group.
Regarding clinical features, disease onset was earlier in women with unfulfilled
reproductive desires. Disease duration was longer in women with fulfilled reproductive
desires, as expected due to age difference. In concordance with a longer disease duration,
disease severity assessed by Hurley stage and the number of draining tunnels were higher
in women with fulfilled reproductive desires. Nevertheless, given the earlier age of onset
in the women with unfulfilled reproductive desires, in the future, they could present more
severe disease features with longer time of evolution than their counterparts with fulfilled
reproductive desires. The higher number of draining tunnels in women with fulfilled
reproductive desires is explained by their longer disease duration and their more severe
disease. Although we did not find differences between affected areas in two groups, the
involvement of the genitalia area might influence pregnancy desires, in agreement with
higher psychological impact on these patients [55].
The decision regarding whether to have children is considered a major life-changing
decision (MLCD), a contributor to the burden of chronic disease that could cause long-term
effects on a patient’s life [54]. Experiences with their first pregnancy, genetic reasons,
disease severity, complication worries, concerns about looking after their health and baby
simultaneously, finances, the potential impact on family life and long-term treatment may
influence the decision of whether or not to have more children, delay plans or have children
through in vitro fertilization [54,56]. Getting married is also considered to be a MLCD [54],
so chronic disease and disease severity could also influence this decision.
Concerning treatment patterns, almost no differences were found based on the ful-
fillment of reproductive desires. Combined oral contraceptives were more frequently
prescribed in women with unfulfilled reproductive desire. They are a safe treatment and
also play a role in avoiding undesired pregnancy [29]. Considering that unplanned preg-
nancies are very frequent [24,43] and deciding to have children is a complicated individual
decision which has to be taken further in advance than among the general population,
combined oral contraceptives may be an adequate treatment for HS patients of childbearing
age. Although having to plan gestations could also mean a decrease in the birth rate, trying
to ensure safety during pregnancy should be the overriding concern. Moreover, it would
be important for clinicians to routinely ask HS women of reproductive age about their
pregnancy intentions and advise those who are planning pregnancies what they can do
to ensure optimal preconception to improve the health of both the woman and child and
improve reproductive outcomes [57]. Many treatments prescribed are safe options for
women of childbearing age. Only acitretin was in the X pregnancy category. Nevertheless,
some frequently used medications are classified as D pregnancy category (doxycycline,
resorcinol, spironolactone and systemic corticosteroids), so clinicians should take women’s
reproductive desire into consideration. Regarding the rates of antibiotic prescription, they
were high in both groups, doxycycline being the most frequent prescribed. It would be
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interesting to conduct targeted and specific antibiotic therapy as a high level of resistance
has been described to antibiotics in HS patients, including rifampicin, clindamycin and
tetracyclines [58].
Biologics were more used in women with fulfilled reproductive desire according to
their more severe and longer disease, while anti-TNF agents seem to be safe before and
during pregnancy [59]. Regarding features of the patients receiving first-line biologics,
women with unfulfilled reproductive desires were younger and had an earlier onset of
the disease, just like the general systemic treatment cohort. Although no differences in
disease severity were found, because of the age difference, it is expected that if women with
unfulfilled reproductive desires reach a similar age as women with fulfilled reproductive
desires, they will have a severe condition. Hurley stage III was more frequent in women
with fulfilled reproductive desires, while AN count was lower in this population. This is
explained by the longer HS duration in this group being related to more tunnels and scars.
This study has some limitations: (1) The sample size is limited, although it was
previously calculated and the sample was adjusted to the previous calculations; (2) the age
difference between the two HS groups, inherent to the condition studied and the nature
of a descriptive study. The aim of the study was to describe the clinical characteristics
and treatment options for fertile women with HS according to their childbearing desires.
To compare fertility rates, severity or other specific disease features, an age-matched
study would be necessary and falls beyond the scope of this investigation. The strength
of this study is that it provides a first overview regarding factors that could influence
the accomplishment of reproductive desires in HS women and safety treatments during
childbearing. Moreover, it was conducted by a dermatologist working in a specialized HS
clinic with many years of experience treating HS patients.
5. Conclusions
In this study, we present the clinical and treatment profile of HS women of childbearing
age based on the fulfillment of their reproductive desire. A higher educational level similar
to that of the general population, and an earlier disease onset, with potential implications
during teenage and early adulthood in finding a partner may make the fulfillment of
reproductive desires difficult for patients with HS. Many treatments used for HS have a safe
profile during childbearing age. Acitretin should be avoided, while anti-TNF alpha drugs
may be a safe option. This study could help clinicians to achieve a better understanding
of the specific characteristics of HS during childbearing age and consider reproductive
desires when making treatment decisions.
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